Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

Article  CAS  PubMed  Google Scholar 

Bittner S, Knoll G, Fullsack S, Kurz M, Wajant H, Ehrenschwender M (2016) Soluble TL1A is sufficient for activation of death receptor 3. FEBS J 283:323–336

Article  CAS  PubMed  Google Scholar 

Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M (2017) Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 19:110

Article  PubMed  PubMed Central  Google Scholar 

Greisen SR, Kragstrup TW, Thomsen JS, Hansen AS, Krishnamurthy A, Horslev-Petersen K, Hetland ML, Stengaard-Pedersen K, Ostergaard M, Ornbjerg LM et al (2020) Programmed death ligand 2 - a link between inflammation and bone loss in rheumatoid arthritis. J Transl Autoimmun 3:100028

Article  PubMed  Google Scholar 

Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, Scott B, Loza M, Orr C, McGarry T et al (2018) Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE 13:e0192704

Article  PubMed  PubMed Central  Google Scholar 

Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, Saura R, Kurosaka M, Honjo T, Kumagai S (2003) CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 30:1410–1419

PubMed  Google Scholar 

Inaba K, Yashiro T, Hiroki I, Watanabe R, Kasakura K, Nishiyama C (2020) Dual roles of PU.1 in the expression of PD-L2: direct transactivation with IRF4 and indirect epigenetic regulation. J Immunol 205:822–829

Article  CAS  PubMed  Google Scholar 

Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, Fukushima T, Akiba H, Yagita H, Okumura K et al (2003) Blockade of B7–H1 suppresses the development of chronic intestinal inflammation. J Immunol 171:4156–4163

Article  CAS  PubMed  Google Scholar 

Karolova J, Radek M, Helman K, Spacek M, Trneny M, Klener P (2020) PD-1, PD-L1 and PD-L2 expression in mantle cell lymphoma and healthy population. Folia Biol (Praha) 66:117–122

CAS  PubMed  Google Scholar 

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704

Article  CAS  PubMed  Google Scholar 

Khan M, Zhao Z, Arooj S, Fu Y, Liao G (2020) Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol 11:587460

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lazar-Molnar E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC (2008) Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A 105:10483–10488

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meng W, Zhu Z, Jiang X, Too CL, Uebe S, Jagodic M, Kockum I, Murad S, Ferrucci L, Alfredsson L et al (2017) DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis. Arthritis Res Ther 19:71

Article  PubMed  PubMed Central  Google Scholar 

Messal N, Serriari NE, Pastor S, Nunes JA, Olive D (2011) PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol 48:2214–2219

Article  CAS  PubMed  Google Scholar 

Pawlowska A, Kwiatkowska A, Suszczyk D, Chudzik A, Tarkowski R, Barczynski B, Kotarski J, Wertel I (2021) Clinical and prognostic value of antigen-presenting cells with PD-L1/PD-L2 expression in ovarian cancer patients. Int J Mol Sci 22

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001

Article  PubMed  Google Scholar 

Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023–2038

Article  CAS  PubMed  Google Scholar 

Sun C, Mezzadra R, Schumacher TN (2018) Regulation and Function of the PD-L1 Checkpoint. Immunity 48:434–452

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tong M, Fang X, Yang J, Wu P, Guo Y, Sun J (2020) Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity. Immunol Lett 227:96–101

Article  CAS  PubMed  Google Scholar 

Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K et al (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169:5538–5545

Article  CAS  PubMed  Google Scholar 

Yasuoka H, Asai A, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K (2020) Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. Sci Rep 10:10377

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X (2008) Soluble CD276 (B7–H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 123:538–546

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhong X, Tumang JR, Gao W, Bai C, Rothstein TL (2007) PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol 37:2405–2410

Article  CAS  PubMed  Google Scholar